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Abstract A novel G protein-coupled receptor, named GPR12A, 
was cloned by a PCR strategy using degenerate primers designed 
from sequences conserved among receptors for inflammatory me- 
diators. Screening of a human lung cDNA library with GPR12A 
as a probe also identified a closely-related cDNA (GPR6C.1) that 
has been previously reported as GPR4 [13]. GPR12A and 
GPR6C.1 are 46.1% identical in amino acid sequence, but are less 
than 33% identical to any other known receptors. Northern anal- 
ysis revealed that they are expressed prominently in the lung. 
Although the ligands for GPR12A and GPR6C.1 are unknown, 
their similarity suggests that they are receptors for ligands of 
similar or identical chemical nature. 
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1. Introduction 
G protein-coupled receptors mediate cellular responses elic- 
ited by a variety of extracellular stimuli ranging from photons, 
odorants and ions to neurotransmitters, regulatory peptides 
and bioactive lipids [1,2]. Molecular cloning of these seven- 
transmembrane-domain receptors has revealed a large gene 
family with many common structural features [3-5]. The pres- 
ence of some partially conserved regions in the sequences of 
members of this gene family has permitted the use of homolo- 
gous screening and polymerase chain reaction (PCR) amplifica- 
tion to isolated novel receptors [6-11]. In this paper, we report 
the cloning and sequencing of two closely-related G protein- 
coupled receptor candidates that are expressed prominently in 
human lung tissue. 
2. Materials and methods 
2.1. Polymerase chain reaction (PCR) amplification 
Two degenerate oligonucleotides were designed based on the par- 
tially conserved cDNA sequences encoding receptors for interleukin-8, 
ATP (P2u), thrombin, platelet activating factor (PAF) and prosta- 
glandin E 2. The upstream primer, CISVDRY (5'-TGCATC(T/A)(G/ 
C)(C/T)GTIGACCGCT-3') corresponds to the sequence of the third 
transmembrane domain of the receptors. The downstream primer, 
TMVII ( 5"-TAIA( C/T)C( CIT)AIGGGTCIA GI( CIA )( AIT)I( C/ 
G)AGTT-Y) corresponds to the sequence of their seventh transmem- 
brane domain. These primers were used in PCR to amplify eDNA 
fragments encoding novel G protein-coupled receptors from human 
lung and neutrophil cDNAs. The PCR conditions were as follows: 
95°C, 1 min (denaturation); 55°C, 1 min (annealing) and 73°C, 2 min 
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(extension) for 40 cycles. A prominent product of 550 bp was obtained 
and subcloned into pCR-Script vector (Stratagene) for sequence analy- 
sis using the Sequenase 2.0 kit (United States Biochemicals). The se- 
quence of the 550 bp clone (designated GPR12A) was predicted to 
encode aportion of a novel member of the G protein-coupled receptor 
family. 
2.2. eDNA library screening, subcloning and sequencing 
The 550 bp insert of clone GPR12A was 32p-labeled by the random 
primer method and used as a probe to screen a human lung eDNA 
library in 2gt 11 phage (Clontech) under high stringency conditions [12]. 
Of the 1 x 10 6 phage reeombinants screened, two overlapping clones 
were isolated that included the full-length coding region of GPR12A. 
In addition, several overlapping clones with sequences imilar to 
GPR12A were also isolated and designated GPR6C.1. The inserts of 
these clones were subcloned into pBluescript vector (Stratagene) and 
subjected to unidirectional deletion using the Erase-a-Base system 
(Promega). DNA sequences on both strands were determined by using 
the Sequenase kit. The sequences of GPR12A and GPR6C.1 were 
assembled and analyzed by the IntelliGenetics Suite computer program. 
2.3. Eukaryotic expression and functional analys& 
eDNA fragments of 1.3 kb and 1.4 kb encoding the predicted full- 
length proteins of GPR12A and GPR6C.1, respectively, were sub- 
cloned into the pRC/CMV expression vector (Invitrogen). These con- 
structs were transiently transfected into human embryonic kidney 293 
cells by LipofectAmine (Gibco BRL). To obtain stable transfectants in 
human myelogenous leukemic K562 cells, the expression constructs 
were transfected by electroporation at a field strength of 150-200 V/mm 
and a pulse-length of 2-8 ms using BTX Transfector 300 (BTX Inc.). 
Cells that survived in the medium containing the neomycin analog 
G418 (500 pg/ml) were selected 3weeks after electroporation. The RNA 
transcripts for GPR12A and GPR6C.1 in K562 stable transfectants 
were detectable by RT-PCR. The transient 293 transfectants were 
tested for radioligand-receptor binding with 1 nM 3H-labeled ligands 
in the presence or absence of 1 gM unlabeled ligands as competitors 
using a standard filter assay. The intracellular calcium mobilization i  
the transient and stable transfectants evoked by 1 pM ligands was 
measured by using Indo-1 as an indicator on an LS50B fluorescence 
spectrometer (Perkin-Elmer). 
2.4. Northern blot analysis 
The 1.3 kb and 1.4 kb eDNA inserts that encode full-length coding 
regions of GPR12A and GPR6C.1 were labeled with 32p and used as 
a probe in a Northern blot analysis. A human multiple tissue Northern 
blot containing 2 pg of poly(A) ÷ RNA in each lane (Clontech) was 
hybridized and washed under high stringency conditions [12]. Exposure 
to Kodak XAR film was for 24 h at -70°C with one intensifying screen. 
3. Results and discussion 
A predominant PCR product of 550 bp was amplified from 
human lung eDNA using degenerate primers C ISVDRY and 
TMVII ,  cloned and sequenced. The DNA sequence of clone 
GPR12A suggested that it may encode a portion of a novel 
member of the G protein-coupled receptor family. This eDNA 
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Fig. 1. Alignment of amino acid sequences of GPR12A and GPR6C. 1. 
Gaps, indicated by hyphen, are introduced to obtain maximal homol- 
ogy. Identical residues are aligned by vertical bars. The approximate 
positions of the putative transmembrane domains are underlined and 
labeled as I through VII. The + indicates potential N-linked glycosyla- 
tion sites. The '*' represents potential phosphorylation sites for protein 
kinase A, whereas the '^' indicates potential phosphorylation site for 
protein kinase C. The nucleotide sequences of GPR 12A and GPR6C. 1 
have been deposited inthe Genbank database under accession numbers 
U35398 and U35399, respectively. 
fragment was used as a probe to screen under high stringency 
conditions 1 × 106 recombinants of a human lung cDNA li- 
brary. Two overlapping clones that include DNA sequence 
identical to that of GPR 12A were isolated for further analyses. 
The optimal open reading frame of GPR12A has 1095 bp, 
which encodes a putative receptor protein of 365 amino acids 
(Fig. 1). In common with all G protein-coupled receptors, 
GPR12A has seven highly hydrophobic regions of 20-23 resi- 
dues. It also contains 3 potential N-linked glycosylation sites 
at Asn 3, Asn s and Asn s6 and seven potential phosphorylation 
sites for protein kinase A in the second and third intracellular 
loops and in the carboxyl-terminal cytoplasmic tail. 
In the course of screening the human lung cDNA library with 
the 550 bp fragment of GPR12A as a probe, we also isolated 
several overlapping clones that have DNA sequences very sim- 
ilar but not identical to the sequence of GPR12A. These over- 
lapping clones, collectively designated GPR6C. 1, are more fre- 
quently represented in the human lung cDNA library than 
GPR12A. The overall DNA sequence of GPR6C.1 is 65.3% 
identical to that of GPR12A. In one continuous 100 bp stretch 
in the 550 bp probe sequence their identity is 85%, which may 
explain the isolation of GPR6C. 1 by using GPR 12A as a probe 
under high stringency conditions. 
The 1086 bp open reading frame of GPR6C.1 encodes a 
protein of 362 amino acids that is 46.1% identical to GPR 12A. 
Similar to GPR12A, GPR6C. 1 also possesses even hydropho- 
bic regions with several potential N-linked glycosylation sites 
and phosphorylation sites (Fig. 1). Recently, we became aware 
that Heiber and colleagues published the sequence ofan orphan 
receptor, GPR4 [13]. The protein sequence of GPR6C.1 is al- 
most identical to that of GPR4 except 15 amino acids in the 
carboxyl-terminus. This difference may reflect sequence poly- 
morphism, differential mRNA splicing or sequencing error of 
the same gene. 
A search of the Swiss-Prot database (release 31) showed that 
GPR 12A and GPR6C. l (GPR4) are unique members of the G 
protein-coupled receptor family. Less than 33% sequence ho- 
mology was detected to any other known G protein-coupled 
receptors. Their closest relatives are P2v ATP purinoceptor [14], 
Pzu ATP purinoceptor [15,16], somatostatin receptor type 5 
[17], thrombin receptor [18] and PAF receptor [19,20]. Com- 
pared to most other G protein-coupled receptors, features 
unique to GPR12A and GPR6C.1 include a phenylalanine in-
stead of a tryptophan i the CFXP sequence of the sixth trans- 
membrane domain, and an aspartate instead of an asparagine 
in DPXXY of the seventh transmembrane domain. Sharing 
these features are the receptors for ATE PAF, thrombin and 
prostanoids [21]. Heiber et al. suggested that the aspartate in 
the seventh transmembrane domain may render this unique 
group of receptors conformations different from most other 
receptors in binding to their ligands [13]. 
The distribution of mRNA for GPR12A and GPR6C.1 in 
human tissues was examined by Northern blot analysis (Fig. 2). 
Both GPR12A and GPR6C.1 are most abundantly expressed 
in human lung. The 3.1 kb transcript of GPR12A was also 
present in the placenta, spleen and testis. Two transcripts (2.4 
kb and 3.3 kb) of GPR6C. 1 were observed in the lung, kidney, 
heart, liver, skeletal muscle and ovary, whereas only the 2.4 kb 
transcript was seen in the placenta. The significance of the 
presence of two different transcripts for GPR6C. 1 is unknown. 
In order to identify the ligands for GPR12A and GPR6C. 1, 
transient expression of their full-length coding regions con- 
structed in expression vector pRC/CMV were performed in 293 
cells. Stable transfectants were also established in K562 cells for 
detection of functions that cannot be done in 293 cells due to 
high levels of background endogenous activities (i.e., intracellu- 
lar calcium mobilization i duced by ATP and lysophosphatidic 
acid). In our attempts to identify the binding ligands for these 
putative receptors, [3H]leukotriene D4(LTD4), [3H]-leukotriene 
B4 (LTB4), [3H]PAF, [3H]5-hydroeicosatetraenoic acid (HETE) 
and [3H]lipoxin A4 did not specifically bind to the transient 
transfectants. LTD4, LTB4, 5-HETE, ATP and lysophosphat- 
idic acid (LPA) did not significantly increase intracellular cal- 
cium concentrations over untransfected control cells in the 
transient and stable transfectants (Table 1). Since we do not 
Table 1 
Ligand binding and intracellular calcium mobilization assays of 
GPRI2A and GPR6C.1 transient and stable transfectants 
Ligand Specific [3]ligand Increase of [Ca2+]i 
(1/~M) binding (total- (% of un-transfected 
nonspecific binding) controls) 
Control I(PGE2)* 12,900 _+ 1,500 dpm 240 + 40 (293 cell) 
LTB 4, LTD 4, < 10% of total dpm < 10 (293 cell) 
PAF 5-HETE, 
LipoxinA4 
Control 2 (VIP)* not done 190 + 20 (K562 cell) 
ATE LPA not done < 10 (K562 cell) 
*Cells in Control 1 and Control 2 are 293 transient transfectants of 
human prostaglandin E2receptor EP3 subtype [22] and K562 stable 
transfectants of human vasoactive intestinal polypeptide r ceptor [23], 
respectively. 2 x 105 cells and 1 × 104 cells/ml were used in binding and 
[Ca 2+] assays, respectively. Values are mean + S.E.M. of at least hree 
determinations. 
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Fig. 2. Northern blot analysis of GPR 12A (panel A) and GPR6C. 1 (panel B). The positions of RNA molecular weight markers are indicated at the 
left side. The tissue sources of RNA in lane: 1 = heart, 2 = brain, 3 = placenta, 4 = lung, 5 = liver, 6 = skeletal muscle, 7 = kidney, 8 = pancreas, 
9 = spleen, 10 = thymus, 11 -- prostate, 12 = testis, 13 = ovary, 14 = small intestine, 15 = colon, 16 = peripheral blood leukocytes. 
know whether the functional receptor proteins are properly 
expressed and coupled to signaling pathways in these heterolo- 
gous cells, at this point we can not definitively exclude the 
possibility that the compounds we have tested can indeed inter- 
act with GPR12A and GPR6C.1. The sequence similarity of 
GPR12A and GPR6C.1, however, implies that they are recep- 
tors for ligands of similar chemical structure or receptor sub- 
types for the same ligand. 
References 
[1] Dohlman, H.G., Thorner, J., Caron, M.G. and Lefkowitz, R.J. 
(1991) Annu. Rev. Biochem. 60, 653 688. 
[2] Strader, C.D., Fong, T.M., Garziano, M.E and Tota, M.R. (1995) 
FASEB J. 9, 745-754. 
[3] Probst, W.C., Snyder, L.A. Schuster, D.I., Brosius, J. and Sealfon, 
S.C. (1992) DNA Cell Biol. 11, 1-20. 
[4] Strader, C.D., Fong, T.M., Tota, M.R., Underwood, D. and 
Dixon, R.A.F. (1994) Annu. Rev. Biochem. 63, 101-132. 
[5] Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6, 180-190. 
[6] Libert, F., Parmentier, M., Lefort, A., Dinsart, C., Van Sande, J., 
Maenhaut, C., Simons, M.-J., Dumont, J.E. and Vassart, G. 
(1989) Science 244, 569-572. 
[7] Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. and 
Bonner, T.I. (1990) Nature 364, 561 564. 
[8] Eva, C., Keinanen, K., Monyer, J., Seeburg, R and Sprengel, R. 
(1990) FEBS Lett. 271, 81-84. 
[9] Monsma, F.J., Mahan, L.C., Mcvittie, L.D., Gerfen, C.R. and 
Sibley, D.R. (1990) Proc. Natl. Acad. Sci. USA 87, 6723-6727. 
[10] Zhou, Q.-Y., Grandy, D.K., Thambi, L., Kushner, J.K., Van Tol, 
H.H.M., Cone, R., Pribnow, D., Salon, J., Bunzow, J.R. and 
Civelli, O. (1990) Nature 347, 76-80. 
[11] Sunahara, R.K., Niznik, H.B., Weiner, D.M., Stormann, T.M., 
Brann, M.R., Kennedy, J.L., Gleernter, J.E., Rozmahel, R., Yang, 
Y., Israel, Y., Seeman, P. and O'Dowd, B.F. (1990) Nature 347, 
80-83 
[12] Sambrook, J., Fritsh, F. and Maniatis, T. (1989) Molecular Clon- 
ing, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 
[13] Heiber, M., Docherty, J.M., Girish, S., Nguyen, T., Cheng, R., 
Heng, H.H.Q., Marchese, A., Tsui, L.-C., Shi, S., Goerge, S.R. and 
O'Dowd, B.F. (1995) 14, 25-35. 
[14] Webb, T.E., Simon, J., Krishek, B.J., Bateson, A.N., Smart, T.G., 
King, B.F., Burnstock, G. and Barnard, E.A. (1993) FEBS Lett. 
324, 219-225. 
[15] Lustig, K.D., Shiau, A.K., Brake, A.J. and Julius, D. (1993) Proc. 
Natl. Acad. Sci. USA 90, 5113 5117. 
[16] Parr, C.E., Sullivan, D.M., Paradiso, A.M. Lazabrowski, E.R., 
Butch, UH., Olsen, J.C., Erb, L., Weisman, G.A., Boucher, R.C. 
and Turner, J.T. (1994) Proc. Natl. Acad. Sci. USA 91, 3275- 
3279. 
[17] Panetta, R., Greenwood, M.T., Warszynska, A., Demchyshyn, 
L.L., Day, R., Niznik, H.B., Srikant, C.B. and Patel, Y.C. (1993) 
Mol. Pharmacol. 45, 417-427. 
124 S. An et al./FEBS Letters 375 (1995) 121-124 
[18] Vu, T.-H.H., Hung, D.T., Wheaton, V.I. and Coughlin, S.R. 
(1991) Cell 64, 1057-1068. 
[19] Honda, Z.-I., Nakamura, M., Miki, I., Minami, M., Watanabe, T., 
Seyama, Y., Okado, H., Toh, H., Ito, K., Miyamoato, T. and 
Shimizu, T. (1991) Nature 349, 342-346. 
[20] Ye, R.D., Prossnitz, E.R., Zou, A.M. and Cochrane, C.G. (1991) 
Biochem. Biophys. Res. Commun. 180, 105-111. 
[21] Coleman, R.A., Smith, W.L. and Narumiya, S. (1994) Pharmacol. 
Rev. 46, 205-229. 
[22] Yang, J., Xia, M., Goetzl, E.J. and An, S (1994) Biochem. Biophys. 
Res.Comm. 198, 999-1006 
[23] Sreedharan, S.P., Patel, D.R., Huang, J. and Goetzl, E.J. (1993) 
Biochem. Biophys. Res. Commun. 193, 546-553 
